Product Information
ZEPBOUND 12.5 MG/0.5 ML PEN is a brand product labeled by Eli Lilly and Company, priced at $525.8487 per ML under NDC 00002246080. Its NADAC has been published 137 times since Feb 21, 2024.
FDA first approved this application on Nov 8, 2023.
Strength
12.5 mg/.5mL
Manufacturer
Eli Lilly and CompanyNDC
00002246080
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
TIRZEPATIDEApproval Type
New Drug (NDA)
FDA Application
NDA217806FDA Approved
11/8/2023
On Market Since
11/8/2023
Pharmacological Classes
Price Statistics
The NADAC for ZEPBOUND 12.5 MG/0.5 ML PEN has been published 137 times since Feb 21, 2024, and over the history we have for it it has risen 2.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $525.8487 per ML |
|---|---|
| All-time high | $542.2130 (Feb 25, 2026) |
| All-time low | $510.3780 (Sep 18, 2024) |
| 52-week high | $542.2130 |
| 52-week low | $525.7374 |
| Median price | $525.7374 |
| Average price | $520.7683 |
| Largest weekly change | +3.0% (Feb 25, 2026) |
| Weeks tracked | 137 |
| Tracking since | Feb 21, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tirzepatide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZEPBOUND 12.5 MG/0.5 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for ZEPBOUND 12.5 MG/0.5 ML PEN, manufactured by Eli Lilly and Company, is $525.8487 per ML (NDC 00002246080), effective Sep 30, 2026.
How has the price of ZEPBOUND 12.5 MG/0.5 ML PEN changed over time?
Over the history we have for it, the NADAC for ZEPBOUND 12.5 MG/0.5 ML PEN has risen 2.7%. It has been tracked across 137 weekly CMS publications since Feb 21, 2024.
What are the highest and lowest recorded NADAC prices for ZEPBOUND 12.5 MG/0.5 ML PEN?
Since Feb 21, 2024, the NADAC for ZEPBOUND 12.5 MG/0.5 ML PEN has ranged from a low of $510.3780 (Sep 18, 2024) to a high of $542.2130 (Feb 25, 2026), with a median of $525.7374 per ML.
Are there cheaper alternatives to ZEPBOUND 12.5 MG/0.5 ML PEN?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ZEPBOUND 12.5 MG/0.5 ML PEN in a comparable dosage form, but none are currently priced below it.
Who manufactures ZEPBOUND 12.5 MG/0.5 ML PEN?
ZEPBOUND 12.5 MG/0.5 ML PEN (NDC 00002246080) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.